The recently revised European Society for Medical Oncology (ESMO) guidelines recommend assessing PIK3CA mutation status in HR+/HER2− metastatic BC as part of routine clinical practice (Gennari et al. 2021). This evidence concerns the gene PIK3CA and breast cancer.